NewcelX (NCEL) Total Current Liabilities (2019 - 2025)
NewcelX (NCEL) posted quarterly Total Current Liabilities of $4.2 million for Q4 2025, down 52.86% year-over-year from $8.9 million in Q4 2024, and down 73.01% quarter-over-quarter from $15.5 million in Q2 2025.
NewcelX (NCEL) Total Current Liabilities (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Total Current Liabilities for 7 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 52.86% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (down 52.86% YoY), while the FY2025 annual figure was $4.2 million, down 52.86% from the prior year.
- Total Current Liabilities eased to $4.2 million in Q4 2025 per NCEL's latest filing, from $15.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $15.5 million in Q2 2025 and bottomed at $1.2 million in Q2 2021.
- Historically, Total Current Liabilities has averaged $4.8 million across 5 years, with a median of $3.5 million in 2022.
- Annual changes were most pronounced in 2021 — Total Current Liabilities slumped 66.64% — and 2025, when it surged 332.8%.
- NewcelX's Total Current Liabilities stood at $2.4 million in 2021, then climbed by 24.53% to $3.0 million in 2022, then grew by 17.07% to $3.5 million in 2023, then jumped by 153.97% to $8.9 million in 2024, then slumped by 52.86% to $4.2 million in 2025.
- Business Quant data shows NCEL's Total Current Liabilities at $4.2 million in Q4 2025, $15.5 million in Q2 2025, and $8.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.20 Mn |
| Jun 30, 2025 | 15.54 Mn |
| Dec 31, 2024 | 8.90 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Jun 30, 2022 | 3.41 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Jun 30, 2021 | 1.19 Mn |
| Dec 31, 2020 | 7.20 Mn |
| Dec 31, 2019 | 4.04 Mn |